The Efficacy and Safety of tDCS in Patients With Mild to Moderate Major Depressive Disorder (NCT04720040) | Clinical Trial Compass
CompletedNot Applicable
The Efficacy and Safety of tDCS in Patients With Mild to Moderate Major Depressive Disorder
South Korea65 participantsStarted 2019-12-23
Plain-language summary
This study evaluated the effectiveness and safety of improving depressive symptoms by applying tDCS for 6 weeks to patients with mild to moderate depression.
Who can participate
Age range19 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Has a diagnosis of a major depressive disorder as confirmed by the DSM-V and MINI (without psychotic features)
* Patients with a K-BDI-II score of 14 or more and 28 or less
* In the case of patients who have previously administered antidepressants, antipsychotics, and anticonvulsants for at least 1 week, Patients with sufficient drug treatment periods of at least 5 times the drug half-life.
Exclusion Criteria:
* Patients diagnosed with Axis I disorders other than major depressive disorder
* Patients diagnosed with other depressive disorders besides major depressive disorder
* Patients who have attempted suicide within 6 months of screening
* Patients who are considered to have problems with EEG and DC stimulation electrode attachment due to scalp deformity, inflammatory reaction, or other dermatological problems
* Patients judged to have other reasons for prohibition of use of tDCS medical devices
* Patients currently taking antidepressants